Refine by
Cirrhosis Articles & Analysis
25 news found
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] PreHevbri is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 and significantly outperformed AFP, the most common biomarker used for HCC detection today. ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbrio™ VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About VBI’s 3-Antigen HBV Vaccine VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbri VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
Fluid overload is a frequent complication of many large diseases – including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure – with diuretic resistance being widespread. The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within ...
An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma. About PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] / PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis ...
Fluid overload is a frequent complication of many large diseases – including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure – with diuretic resistance being widespread. The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within ...
NASH is characterized by inflammation and excessive fat accumulation in the liver that may progress to fibrosis, cirrhosis, liver cancer, and eventually liver failure. There is currently no FDA approved therapeutic available for NASH and liver fibrosis patients. ...
“In people with AATLD, misfolded AAT aggregates in the liver and causes liver injury that may progress to liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver transplantation is currently the only option for individuals with this rare condition who progress to liver failure, underscoring the need for a safe and effective therapeutic approach that can reduce the ...
With 100 million Americans affected by fatty liver disease, one-fifth will progress to a more severe form of the condition and are at further risk of developing cirrhosis and liver cancer. Despite the increasing prevalence of this condition, many patients go undiagnosed, in large part due to the lack of an efficient diagnostic tool. ...
Based on the grade of severity of cirrhosis, it has been rated A to C. All the patients who belong to grade C and most of the grade B patients should be considered for liver transplantation treatment. What are the common symptoms of liver cirrhosis? The patient who has this ailment can experience- Black stool. ...
This is a life-threatening and serious liver disease, and this is be caused by many liver conditions. For instance, cirrhosis is one of the common causes of end-stage liver disease. It is one of the chronic liver diseases and generally happens when healthy liver tissue is replaced by scar tissue. ...
Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company has received the second $3 million tranche of the $10 million Series A funding round from Shanghai Fosun Pharmaceutical Co., Ltd. ...
As NASH evolves, over time it can result in fibrosis in the liver, potentially leading to cirrhosis or cancer. Even 35 years after its formal description, no treatments have been shown to be universally effective, and even those which work partially have serious side effects. ...
Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company has received the first $3 million tranche of the $10 million Series A funding round from Shanghai Fosun Pharmaceutical Co., Ltd. ...
Glycotest Inc., Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today the close of a Series A funding round of $10 million from Shanghai Fosun Pharmaceutical Co., Ltd. ...
If left untreated, both infections can lead to cirrhosis of the liver, liver cancer, and death. Timely diagnosis is the key to controlling these diseases and stemming new infections. ...
If left untreated, both infections can lead to cirrhosis of the liver, liver cancer, and death. Timely diagnosis is the key to controlling these diseases and stemming new infections. ...